Gastric cancer adjuvant immunotherapy FDA approval with PD-1 inhibitor resected tumor treatment
RegulatoryBusiness Wire

Merck Receives FDA Approval for Keytruda as Adjuvant Therapy in Resected Gastric Cancer

Merck announces FDA approval of pembrolizumab (Keytruda) as adjuvant therapy for patients with resected gastric or gastroesophageal junction adenocarcinoma.

Merck today announced that the FDA has approved Keytruda (pembrolizumab) as adjuvant therapy for patients with resected gastric or gastroesophageal junction (GEJ) adenocarcinoma following preoperative platinum-containing chemotherapy. The approval was based on the Phase 3 KEYNOTE-585 trial demonstrating a statistically significant improvement in event-free survival. This approval provides a new treatment option for patients with resected gastric/GEJ cancer and represents the first immunotherapy approved in the adjuvant setting for this disease.

Original Source

Business Wire
Share:

Previous

AstraZeneca Reports Positive Phase 3 COURSE Trial Results for Tezepelumab in COPD

Next

Pfizer Reports Phase 3 VERITAC-2 Data for Vepdegestrant in ER-Positive Breast Cancer